← Browse by Condition
Medical Condition

ovarian cancer

Total Trials
48
Recruiting Now
48
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2

Ovarian cancer trials are shaped by the central role of BRCA1/2 mutation status and homologous recombination deficiency (HRD) in predicting response to PARP inhibitors β€” now standard maintenance therapy after first-line platinum-based chemotherapy for BRCA-mutated and HRD-positive disease. Despite PARP inhibitor approvals, platinum-resistant and BRCA wild-type advanced ovarian cancer remains a major unmet need driving frontline clinical research.

Active research includes next-generation PARP inhibitor combinations with anti-angiogenic agents and immune checkpoint inhibitors, mirvetuximab soravtansine (ADC targeting folate receptor alpha) in platinum-resistant disease, niraparib dose optimization, and VEGF/angiopoietin bispecific antibodies. Trials also evaluate intraperitoneal and heated intraperitoneal approaches for recurrent disease.

Most ovarian cancer trials require germline BRCA testing and often somatic tumor HRD testing; prior platinum therapy and number of prior lines determine eligibility for many studies.

Frequently Asked Questions — ovarian cancer Clinical Trials

How many clinical trials are currently recruiting for ovarian cancer?
ClinicalMetric currently tracks 48 actively recruiting clinical trials for ovarian cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 48. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for ovarian cancer?
ovarian cancer research spans Phase 1 (21 trials), Phase 2 (16 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a ovarian cancer clinical trial?
Eligibility criteria for ovarian cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
21
Phase 2
16
Phase 3
3
Top Sponsors
University of California, Irvine 2 trials
Hospices Civils de Lyon 2 trials
Centro di Riferimento Oncologico - Aviano 2 trials
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2 trials
Corcept Therapeutics 1 trial

Recruiting Clinical Trials

NCT06906341 Phase 2
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Enrollment
270 pts
Location
United States, Belgi...
Sponsor
Corcept Therapeutics
View Trial →
NCT05103683 Phase 1
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Enrollment
90 pts
Location
United States, South...
Sponsor
TORL Biotherapeutics, LLC
View Trial →
NCT07361471
Recruiting
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
Enrollment
55 pts
Location
France
Sponsor
Centre Jean Perrin
View Trial →
NCT05071937 Phase 2
Recruiting
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Enrollment
33 pts
Location
United States
Sponsor
Alexander B Olawaiye, MD
View Trial →
NCT05739981 Phase 1, Phase 2
Recruiting
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment
30 pts
Location
United States
Sponsor
Imunon
View Trial →
NCT06305299 Phase 1
Recruiting
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Enrollment
27 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C...
View Trial →
NCT05877599 Phase 1
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Enrollment
45 pts
Location
United States
Sponsor
AstraZeneca
View Trial →
NCT05364879
Recruiting
Prehabilitation for Ovarian Cancer Patients
Enrollment
108 pts
Location
Canada
Sponsor
Nova Scotia Health Authority
View Trial →
NCT04520139 Phase 1, Phase 2
Recruiting
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
Enrollment
102 pts
Location
United States
Sponsor
University of California, Irvi...
View Trial →
NCT05983432 Phase 1
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Enrollment
470 pts
Location
United States, Franc...
Sponsor
SystImmune Inc.
View Trial →
NCT02429687 Phase 3
Recruiting
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Enrollment
129 pts
Location
China
Sponsor
Beihua Kong
View Trial →
NCT06024109
Recruiting
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
Enrollment
132 pts
Location
Germany, Spain
Sponsor
Aesculap AG
View Trial →
NCT05113368 Phase 2
Recruiting
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Enrollment
31 pts
Location
United States
Sponsor
Sarah K. Lynam MD
View Trial →
NCT06392997
Recruiting
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
Enrollment
2,500 pts
Location
France
Sponsor
ZIWIG
View Trial →
NCT05645510
Recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Enrollment
75 pts
Location
Canada
Sponsor
University of Alberta
View Trial →
NCT06242470 Phase 1
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
Enrollment
250 pts
Location
United States, Austr...
Sponsor
MacroGenics
View Trial →
NCT07564141 Phase 3
Recruiting
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Enrollment
688 pts
Location
United States
Sponsor
Genmab
View Trial →
NCT05377996 Phase 1, Phase 2
Recruiting
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Enrollment
360 pts
Location
United States
Sponsor
Day One Biopharmaceuticals, In...
View Trial →
NCT07285941 Phase 2
Recruiting
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Enrollment
20 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
View Trial →
NCT05000294 Phase 1, Phase 2
Recruiting
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Enrollment
29 pts
Location
United States
Sponsor
University of Florida
View Trial →
NCT07733505 Phase 1
Recruiting
Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?
Enrollment
10 pts
Location
Denmark
Sponsor
Odense University Hospital
View Trial →
NCT03787056
Recruiting
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Enrollment
410 pts
Location
France
Sponsor
Hospices Civils de Lyon
View Trial →
NCT06618235 Phase 1, Phase 2
Recruiting
Trial of THEO-260 in Ovarian Cancer Patients
Enrollment
44 pts
Location
Spain, United Kingdo...
Sponsor
Theolytics Limited
View Trial →
NCT04847063 Phase 1
Recruiting
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Enrollment
60 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT07424547 Phase 1
Recruiting
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Enrollment
386 pts
Location
United States
Sponsor
Conjupro Biotherapeutics, Inc.
View Trial →
NCT06840886 Phase 1
Recruiting
A Study of PHST001 in Advanced Solid Tumors
Enrollment
272 pts
Location
United States
Sponsor
Pheast Therapeutics
View Trial →
NCT06229522
Recruiting
Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).
Enrollment
150 pts
Location
Italy
Sponsor
Centro di Riferimento Oncologi...
View Trial →
NCT06303505 Phase 1, Phase 2
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Enrollment
250 pts
Location
United States, Belgi...
Sponsor
Tubulis GmbH
View Trial →
NCT07070973
Recruiting
Proactive Hemodynamic Management During Cytoreductive Surgery and HIPEC
Enrollment
52 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT04789694 Phase 3
Recruiting
Prehabilitation in Gynaecological Cancer Patients
Enrollment
64 pts
Location
Czechia
Sponsor
Charles University, Czech Repu...
View Trial →
NCT06580002 Phase 2
Recruiting
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Enrollment
75 pts
Location
United States
Sponsor
University of California, Irvi...
View Trial →
NCT05842629
Recruiting
Improved Diagnosis of Ovarian Cancer
Enrollment
1,700 pts
Location
Denmark
Sponsor
University of Aarhus
View Trial →
NCT07039331
Recruiting
Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients
Enrollment
54 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT04710797
Recruiting
Lymphadenectomy in Early Ovarian Cancer
Enrollment
656 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06028724
Recruiting
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Enrollment
782 pts
Location
Italy
Sponsor
Centro di Riferimento Oncologi...
View Trial →
NCT01034033
Recruiting
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Enrollment
3,300 pts
Location
United States
Sponsor
Stanford University
View Trial →
NCT04606914 Phase 2
Recruiting
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment
70 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT06910657 Phase 1
Recruiting
IDOV-Immune for Advanced Solid Tumors
Enrollment
78 pts
Location
United States, Austr...
Sponsor
ViroMissile, Inc.
View Trial →
NCT06268665 Phase 2
Recruiting
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Enrollment
86 pts
Location
United States
Sponsor
University of California, Davi...
View Trial →
NCT07610798 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Enrollment
178 pts
Location
China
Sponsor
Shenzhen Ionova Life Sciences ...
View Trial →
NCT07524322 Phase 1
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Enrollment
63 pts
Location
United States
Sponsor
Regor Pharmaceuticals Inc.
View Trial →
NCT07156253 Phase 1
Recruiting
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Enrollment
110 pts
Location
China
Sponsor
Hangzhou SynRx Therapeutics Bi...
View Trial →
NCT05912972
Recruiting
Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Enrollment
13,500 pts
Location
South Korea
Sponsor
Asan Medical Center
View Trial →
NCT07216105 Phase 1
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Enrollment
119 pts
Location
United States
Sponsor
Fate Therapeutics
View Trial →
NCT07341737 Phase 1, Phase 2
Recruiting
SL-28 for Advanced Solid Tumours
Enrollment
60 pts
Location
Australia
Sponsor
Second Life Therapeutics
View Trial →
NCT04714957
Recruiting
PITCHER (Peritoneal Carcinomatosis Heterogeneity)
Enrollment
20 pts
Location
France
Sponsor
Hospices Civils de Lyon
View Trial →
NCT06851429
Recruiting
Ovarian Cancer Identification on CT Using Deep Learning
Enrollment
12,578 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
View Trial →
NCT06695845 Phase 2
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Enrollment
200 pts
Location
United States, South...
Sponsor
Jazz Pharmaceuticals
View Trial →

Related Conditions

breast cancer (18) endometrial cancer (15) colorectal cancer (10) cervical cancer (7) fallopian tube cancer (6) non small cell lung cancer (6) melanoma (6) prostate cancer (6) gastric cancer (6) lung cancer (5) esophageal cancer (5) bladder cancer (4)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology